Canadians Follow GARDASIL Money Trail

Canadians Follow GARDASIL Money Trail

by Barbara Loe Fisher

Abraham Lincoln once said "You can fool some of the people all of the time, and all of the people some of the time, but you cannot fool all of the people all of the time." It is getting increasingly difficult for multi-national pharmaceutical corporations to hide the fact that they are engaging politicians from both sides of the aisle in the US, Canada and Europe to provide them with an assured, blockbuster market for new vaccines like Merck's GARDASIL.
http://www.agoracosmopolitan.com/home/Frontpage/2007/10/29/01919.html

It doesn't seem to matter how poorly a new vaccine has been tested or how many people die or become seriously injured after it has hit the streets. Those deaths and injuries are conveniently written off by government officials as a " coincidence" and the exploitation of the people by drug companies for profit continues without a pause.

Wall Street is doing a good job keeping us up-to- date with just how much money big pharmaceutical corporations are raking in now that Congress bowed to Big Pharma pressure and pretty much removed all liability from the business of making and selling vaccines in the 1980's and, again after September 11, 2001, in the name of "national security" and "the greater good" and the admonition that "disease is just a plane ride away." Mandating every new vaccine the drug industry produces and taking away all exemptions to vaccination is another money making guarantee.

Revenue predictions for Merck are that GARDASIL profits will climb from $300 million to $4 billion over the next year. Sanofi Pasteur, another mega giant vaccine maker is growing its vaccine sector by 50 percent. "It's a great trend and I would buy Merck" advises one Wall Street guru.
http://www.thestreet.com/funds/tv-recap/10388133.html

One day enough voters will figure out that vaccinating 300 million Americans and 33 million Canadians with multiple vaccines from cradle to the grave has more to do with keeping drug companies in the money than keeping people healthy. Then the politicians, who have committed hundreds of millions of taxpayer dollars to underwrite new product rollouts for pharmaceutical companies selling vaccines while shielding them from all liability for vaccine injuries and deaths, will be looking for another job.





--------------------------------------------------------------------------------




The Stephen Harper Conservative minority government earlier this year made a decision to spend $300 million on a campaign to inoculate females nine to 13 against cervical cancer. Sounds like great leadership on a critical health issue doesn't it? The problem is that the decision appears to be motivated to financially support the U.S. Big Business Pharmaceutical interests that developed the vaccine.... The American-based National Vaccine Information Center (NVIC) had released in February 2007 a new analysis of the U.S. Federal Vaccine Adverse Event Reporting System (VAERS) reports of serious health problems following HPV vaccination (Merck's GARDASIL) during the last six months of 2006....Judicial Watch, a U.S. government watchdog, became concerned while noting large donations to key politicians originating from Merck.... The Toronto Star recently reported that Merck Frosst Canada Ltd hired public relations giant Hill & Knowlton to push the immunization strategies using some well-connected lobbyists...." - Paul Chen, The Canadian (October 30, 2007)

"Gardasil, the human papillomavirus vaccine from Merck, is going to be huge, Cramer and stockpickr.com's James Altucher agreed. It's going from about $300 million to $4 billion in revenue over the next year, and that's just one vaccine, he said. Plus, now they're doing late-stage trials on a hepatitis-B vaccine. "I think if you want a solid 15%, maybe 20% a year for a long time, Merck is a great bet," Altucher said. "This is a re-energized Merck," Cramer said. "It's a really great Merck. It keeps going up. It keeps beating numbers, but it's still only back to where it was a couple of years ago, so I agree with you, I think there's more [room for it] to climb." When Altucher pointed out Sanofi-Aventis (SNY) , where vaccine growth was 50%, Cramer said it is another company that he likes. For years, vaccines were risky, because if something went wrong, it was only a matter of time before a company had a class-action suit against it. "So the drug companies pretty much decided there was no real money in vaccines," Cramer explained. One of the big changes the analysts didn't pick up on is that since then, the plaintiffs' bar has been beaten back, so the litigation risk of vaccines has declined. "It's a great trend and I would buy Merck," Cramer said." - The Street.com (November 2, 2007)